Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Success Of German Cost-Control Law Raises Prospect Of Further Cuts For Pharma

This article was originally published in The Pink Sheet Daily

Executive Summary

Germany's 2011 pharmaceutical prescribing report shows that the cost control law (AMNOG) is fulfilling its purpose, prompting insurers to call for even further pressure on the industry to reduce costs.

Related Content

After Elections, Germany’s Pharma Industry Faces Uncertain Future
German Drug Report Could Mean More Pressure On Pharma Revenues
German Pharma Fears Drug Prescribing Report Will Be Used To Force Down Prices Again
German Reimbursement Decisions Will Remain Officially Opaque In New Law
European Regulatory Round-Up
German Pharma Firms Face Yet Another Price Control Measure
German Pharma Firms Face Yet Another Price Control Measure
Germany's Discount Contracts Are Changing The Pharma Market Landscape





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts